Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Turning Point Therapeutics, Inc. (TPTX)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Turning Point Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Turning Point Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is TPTX. The reporting company's CIK number is 1595893.
The total value of stock buying since 2005 is $33,206,400.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $51,073.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-05-14||Chen Bihua||Option Ex||23,268||2.19||51,073|
|2019-04-22||Baker Brian Lee (VP of Finance and Admin.)||Buy||2,800||18.00||50,400|
|2019-04-22||Lu Hongbo (Director)||Buy||60,000||18.00||1,080,000|
|2019-04-22||Orbimed Capital Gp Vi Llc (Director)||Buy||360,000||18.00||6,480,000|
|2019-04-22||George Simeon (Director)||Buy||325,000||18.00||5,850,000|
|2019-04-22||Countouriotis Athena (President & CEO)||Buy||12,000||18.00||216,000|
|2019-04-22||Gordon Carl L (Director)||Buy||360,000||18.00||6,480,000|
Insider trading activities including stock purchases, stock sales, and option exercises of TPTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Turning Point Therapeutics, Inc. (symbol TPTX, CIK number 1595893) see the Securities and Exchange Commission (SEC) website.